EWTX News and Press, Edgewise Therapeutics Inc. From 06/01/21

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders, today announced that members of its management team will participate in a fireside chat and one-on-one i...

Edgewise Therapeutics (EWTX): Q1 Non-GAAP EPS of -$0.14 beats by $0.01; GAAP EPS of -$4.37 misses by $4.21.Cash and marketable securities of $309.9MPress Release For further details see: Edgewise Therapeutics EPS beats by $0.01

– Completed successful $202.4 million Initial Public Offering (IPO); cash and marketable securities of $309.9 million as of March 31, 2021 – – Initiated Phase 1 MAD study of EDG-5506, a small molecule drug candidate designed to arrest muscle fiber breakdow...

– First cross-sectional, retrospective study to describe selective elevation of fast but not slow skeletal muscle fiber injury biomarkers in BMD and DMD patient samples, published in Muscle & Nerve – – Data supports Edgewise strategy to advance EDG-550...

Edgewise Therapeutics ([[EWTX]] -3.0%) appointed Joanne M. Donovan, M.D., Ph.D. as chief medical officer to be responsible for leading clinical, medical and regulatory strategy and operations for the company’s pipeline, including EDG-5506, the company's lead product candidate...

– Rare disease expert joins as company continues to advance lead muscular dystrophy product candidate in clinical development – Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, sm...

Gainers: CEL-SCI (CVM) +20%, Renalytix RNLX +19%, Chemomab Therapeutics Ltd. (CMMB) +15%, Brooklyn ImmunoTherapeutics (BTX) +13%, Ocugen OCGN +13%.Losers: Evolus EOLS -18%, Precipio (PRPO) -9%, Shineco (TYHT) -8%, Adagene (ADAG)...

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders, announced today the closing of its initial public offering of 12,650,000 shares of its common stock, whi...